We've updated our Privacy Policy to make it clearer how we use your personal data.

We use cookies to provide you with a better experience. You can read our Cookie Policy here.

Advertisement
CEVEC to Launch CAP-T™ Cell System – a Human Transient Expression Technology
Product News

CEVEC to Launch CAP-T™ Cell System – a Human Transient Expression Technology

CEVEC to Launch CAP-T™ Cell System – a Human Transient Expression Technology
Product News

CEVEC to Launch CAP-T™ Cell System – a Human Transient Expression Technology


Want a FREE PDF version of This Product News?

Complete the form below and we will email you a PDF version of "CEVEC to Launch CAP-T™ Cell System – a Human Transient Expression Technology"

First Name*
Last Name*
Email Address*
Country*
Company Type*
Job Function*
Would you like to receive further email communication from Technology Networks?

Technology Networks Ltd. needs the contact information you provide to us to contact you about our products and services. You may unsubscribe from these communications at any time. For information on how to unsubscribe, as well as our privacy practices and commitment to protecting your privacy, check out our Privacy Policy

CEVEC Pharmaceuticals GmbH introduces novel CAP-T™ transient expression system for serum-free and high yield protein production. CAP-T™ Technology is the logic result of today’s demand towards creating an efficient, integrated platform for transient production of complex biologics.

With CAP-T™ customers can proceed from gene to milligram and gram amounts of protein within only two weeks. Fast process times, high yields and authentic human post-translational modifications especially with complex and highly glycosylated proteins are key features and make it an ideal tool for screening, assay development, target validation, drug discovery, early stage pre-clinical drug development, and lead optimization.

Dr. Rainer Lichtenberger, CEO of CEVEC, comments: “Starting with transient protein expression using CAP-T™ and moving forward with stable expression using CAP® cells, CEVEC is now able to offer a continuum for rapid and versatile biopharmaceutical drug development from initial research ideas up to GMP-compliant manufacturing of clinical samples and market supplies.”

CAP-T™ cells are based on CAP® cells and match all their positive features with regard to comprehensive documentation, safety, non-tumor origin, and growth as suspension culture in serum- and protein-free media optimized for industrial use. CAP-T™ is available under flexible research license arrangements.
Advertisement